Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1)

Drug Metabolism Reviews

Volumn 29, Issue 3, 1997, Pages 589-650

  Lewis, David F V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; BENZIMIDAZOLE DERIVATIVE; BENZ[A]ANTHRACENE DERIVATIVE; BIPHENYL DERIVATIVE; CARCINOGEN; CHRYSENE DERIVATIVE; COUMARIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DIBENZODIOXIN DERIVATIVE; ENZYME INDUCING AGENT; HETEROCYCLIC AMINE; MUTAGENIC AGENT; NITROFURAN DERIVATIVE; PHENANTHRENE DERIVATIVE; PHENOL DERIVATIVE; POLYBROMINATED BIPHENYL; POLYCHLORINATED BIPHENYL DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON; RESORUFIN DERIVATIVE; TOLUENE DERIVATIVE;

CARCINOGENICITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; MUTAGENICITY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 0030873260     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602539709037593     Document Type: Review

References (64)

1. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, P. Gotoh, K. Okuda, and D. W. Nebert, DNA Cell Biol., 12 1 (1993).
2. D. R. Nelson et al., Pharmacogenetics, 6, l (1996).
3. F. J. Gonzalez and H. V. Gelboin, Drug Metab. Rev., 26, 165 (1994).
4. D. F. V. Lewis and B. G. Lake, Xenobiotica, 26, 723 (1996).
5. C. Ioannides and D. V. Parke, Drug Metab. Rev., 22, 1 (1990).
6. C. Ionannides and D. V. Parke, Drug Metab. Rev., 25, 485 (1993).
7. O. Hankinson, Annu. Rev. Pharmacol. Toxicol., 35, 307 (1995).
8. H. Reyes, S. Reisz-Porszasz, and O. Hankinson, Science, 256, 1193 (1992).
9. D. W. Nebert, in Cytochrome P-450: Biochemistry and Biophysics (I. Schuster, ed.), Taylor and Francis, London, 1989, p. 484.
10. Y. Fujii-Kuriyama, A. Fujisawa-Sehara, and K. Sogawa, Drug Metab. Rev., 20, 821 (1989).
11. J. P. Whitlock, M. S. Denison, L. K. Durrin, J. M. Fisher, D. R. Galeazzi, and P. B. C. Jones, Drug Metab. Rev., 20, 839 (1989).
12. J. P. Whitlock, Trends Pharm. Sci., 10, 285 (1989).
13. J. Huff, G. Lacier, and A. Tritscher, Annu. Rev. Pharmacol. Toxicol., 34, 343 (1994).
14. P. Kopponen, R. Torronen, J. Maki-Paakkanen, A. von Wright, and S. Karenlampi, Arch. Toxicol., 68, 167 (1994).
15. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Chem.-Biol. Interact., 64, 39 (1987).
16. C. Mansch and L. Zhang, Drug Metab. Rev., 25, 1 (1993).
17. M. A. Denomme, J. Sparling, A. B. Okey, and T. Fujita, Environ. Health Perspect., 61, 21 (1985).
18. S. Safe, S. Bandiera, T. Sawyer, B. Zmudska, G. Mason, M. Romkes, M. A. Denomme, J. Sparling, A. B. Okey, and T. Fujita, Environ. Health Perspect., 61, 21 (1985).
19. D. V. Parke, C. Ioannides, and D. F. V. Lewis, in Toxicology in Europe in the Year 2000 (C. M. Hodel, ed.) Eisevier, Amsterdam, 1986, p. 14.
20. D. F. V. Lewis, T. J. B. Gray, and B. G. Lake, in Drug Metabolism from Molecules to Man (D. J. Benford, J. W. Bridges, and G. G. Gibson, eds.), Taylor and Francis, London, 1987, p. 369.
21. J. P. Landers and N. J. Bunce, Biochem. J., 276, 273 (1991).
22. A. B. Okey and L. M. Vella, Eur. J. Biochem., 127, 39 (1982).
23. A. Poland and J. C. Knutson, Annu. Rev. Pharmacol. Toxicol., 22, 517 (1982).
24. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Biochem. Pharmacol., 35, 2179 (1986).
25. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Chem.-Biol. Interact., 70, 263 (1989).
26. D. V. Parke, C. Ioannides, and D. F. V. Lewis, Hum. Toxicol., 7, 397 (1988).
27. C. L. Golas, R. D. Prokipcak, A. B. Okey, D. K. Manchester, S. Safe, and T. Fujita, Biochem. Pharmacol, 40, 737 (1990).
28. S. Kobayashi, A. Shigihara, H. Ichikawa, A. Tanaka, and S. Tobinaga, Chem. Pharm. Bull., 40, 3062 (1992).
29. M. A. Denomme, K. Homonoko, T. Fujita, T. Sawyer, and S. Safe, Mol. Pharmacol., 27, 656 (1985).
30. S. A. Kafafi, H. K. Said, M. I. Mahmoud, and H. Y. Afeefy, Carcinogenesis, 13, 1599 (1992).
31. A. Poland, E. Glover, and A. S. Kende, J. Biol. Chem., 251, 4936 (1976).
32. D. F. V. Lewis, Xenobiotica, 17, 1351 (1987).
33. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Biochem. Pharmacol., 50, 619 (1995).
34. G. W. Boyd, M. M. Coombs, and C. Ioannides, Toxicology, 95, 27 (1995).
35. G. W. Boyd, Ph.D. thesis, University of Surrey, Guildford, U.K., 1993.
36. A. D. Ayrton, M. McFarlane, R. Walker, S. Neville, M. M. Coombes, and C. Ioannides, Toxicology, 60, 173 (1990).
37. M. M. Coombes, C. Dixon, and A.-M. Kissonerghis, Cancer Res., 36, 4525-4529 (1976).
38. Y.-L. Cheung, T. J. B. Gray, and C. Ioannides, Toxicology, 81, 69 (1993).
39. D. F. V. Lewis, Prog. Drug Metab., 12, 205 (1990).
40. Y.-L. Cheung, J. Snelling, N. N. D. Mohammed, T. J. B. Gray, and C. loannides, Toxicol. Appl. Pharmacol. 39, 203 (1996).
41. D. F. V. Lewis, C. Ioannides, and D. V. Parke, in QSARs and Molecular Modelling: Concepts, Computational Tools and Biological Applications (F. Sanz, ed.), Prous, Barcelona, 1996 , p. 595.
42. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Environ. Health Perspect., 103, 178 (1995).
43. D. F. V. Lewis, C. Ioannides,.and D. V. Parke, Toxicol. Lett., 76, 39 (1995).
44. M. Murray, K. Hetnarski, and C. F. Wilkinson, Xenobiotica, 15, 369 (1985).
45. M. Murray and A. J. Ryan, Chem.-Biol. Interact., 43, 341 (1983).
46. D. F. V. Lewis, B. G. Lake, C. Ioannides, and D. V. Parke, Xenobiotica, 24, 829 (1994).
47. I. Stupans and A. J. Ryan, Biochem. Pharmacol., 33, 131 (1984).
48. D. F. V. Lewis, B. G. Lake, and D. V. Parke, Xenobiotica, 25, 1355 (1995).
49. M. D. Burke, S. Thompson, C. R. Elcombe, J. R. Halpert, T. Haaparanta, and R. T. Mayer, Biochem. Pharmacol., 34, 3337 (1985).
50. M. W. Kennedy, N. K. Carpentier, P. P. Dymerski, and L. S. Kaminsky, Biochem. Pharmacol., 30, 577 (1981).
51. D. F. V. Lewis, Toxicol. Model., 1, 85 (1995).
52. R. A. Mills, C. D. Millis, G. A. Dannan, F. P. Guengerich, and S. D. Aust, Toxicol. Appl. Pharmacol., 78, 96 (1985).
53. D. A. Smith, S. M. Abel, R. Hyland, and B. C. Jones, Xenobiotica, 27 (1997) (in press).
54. P. J. Rugen, C. D. Stern, and S. H. Lamm, Regul. Toxicol. Pharmacol., 9, 273-283 (1989).
55. P. G. Wislocki, K. M. Fiorentini, P. P. Fu, S. J. Yang, and A. Y. H. Lu, Carcinogenesis, 3, 215 (1982).
56. D. F. V. Lewis and D. V. Parke, Mutat. Res., 328, 207 (1995).
57. F. Oesch, H. Glatt, and D. Utesch, Xenobiotica. 18(Supplement 1), 34 (1988).
58. D. F. V. Lewis, H. Moereels, B. G. Lake, C. Ioannides, and D. V. Parke, Drug Metab. Rev., 26, 261 (1994).
59. P. P. Fu, Drug Metab. Rev., 22, 209 (1990).
60. A. R. Maynard, L. G. Petersen, H. S. Posner, and J. D. McKinney, Mol. Pharmacol., 29, 629 (1986).
61. T. Sugimura, K. Wakabayashi, M. Nagao, and H. Esumi, in Food, Nutrition and Chemical Toxicity (D. V. Parke, C. Ioannides, and R. Walker, eds.), Smith-Gordon, London, 1993, p. 259.
62. D. F. V. Lewis, C. Ioannides, R. Walker, and D. V. Parke, Food Addit. Contam., 12, 715 (1995).
63. A. K. Debnath, R. L. Lopez de Compadre, A. J. Shusterman, and C. Mansch, Environ. Mol. Mutagen., 19, 53 (1992).
64. A. K. Debnath, A. J. Shusterman, R. L. Lopez de Compadre, and C. Mansch, Mutat. Res., 305, 63 (1994).